DK3369435T3 - Sammensætning til behandling af inflammatorisk ledsygdom - Google Patents

Sammensætning til behandling af inflammatorisk ledsygdom Download PDF

Info

Publication number
DK3369435T3
DK3369435T3 DK18167083T DK18167083T DK3369435T3 DK 3369435 T3 DK3369435 T3 DK 3369435T3 DK 18167083 T DK18167083 T DK 18167083T DK 18167083 T DK18167083 T DK 18167083T DK 3369435 T3 DK3369435 T3 DK 3369435T3
Authority
DK
Denmark
Prior art keywords
treatment
composition
inflammatory disease
inflammatory
disease
Prior art date
Application number
DK18167083T
Other languages
English (en)
Inventor
Robert Landry
Raymond A Chavez
Linda R Watkins
Original Assignee
Xalud Therapeutics Inc
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xalud Therapeutics Inc, Univ Colorado Regents filed Critical Xalud Therapeutics Inc
Application granted granted Critical
Publication of DK3369435T3 publication Critical patent/DK3369435T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
DK18167083T 2013-07-18 2014-07-17 Sammensætning til behandling af inflammatorisk ledsygdom DK3369435T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361847851P 2013-07-18 2013-07-18
EP14826787.5A EP3021873B8 (en) 2013-07-18 2014-07-17 Composition for the treatment of inflammatory joint disease

Publications (1)

Publication Number Publication Date
DK3369435T3 true DK3369435T3 (da) 2019-11-25

Family

ID=52346725

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14826787.5T DK3021873T3 (da) 2013-07-18 2014-07-17 Sammensætning til behandling af inflammatorisk ledsygdom
DK18167083T DK3369435T3 (da) 2013-07-18 2014-07-17 Sammensætning til behandling af inflammatorisk ledsygdom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14826787.5T DK3021873T3 (da) 2013-07-18 2014-07-17 Sammensætning til behandling af inflammatorisk ledsygdom

Country Status (14)

Country Link
US (4) US10512672B2 (da)
EP (2) EP3369435B1 (da)
JP (3) JP2016525522A (da)
CY (2) CY1120946T1 (da)
DK (2) DK3021873T3 (da)
ES (2) ES2700826T3 (da)
HR (2) HRP20181913T1 (da)
HU (2) HUE042463T2 (da)
LT (2) LT3369435T (da)
PL (2) PL3369435T3 (da)
PT (2) PT3369435T (da)
RS (2) RS57974B1 (da)
SI (2) SI3021873T1 (da)
WO (1) WO2015009955A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3021873T1 (sl) 2013-07-18 2018-12-31 Xalud Therapeutics, Inc. Sestavek za zdravljenje vnetne sklepne bolezni
IL262195B2 (en) * 2016-04-22 2023-09-01 Xalud Therapeutics Inc Methods and preparations for improving the anti-inflammatory effects of interleukin 10
IL299149A (en) * 2020-06-26 2023-02-01 Amgen Inc IL-10 mutants and their related proteins
WO2023114958A1 (en) * 2021-12-16 2023-06-22 Xalud Therapeutics, Inc. Dosing regimen for il-10 encoding expression construct

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US6312680B1 (en) 1990-06-29 2001-11-06 Timothy R. Mosmann Methods of treatment using cytokine synthesis inhibitory factor
WO1994004180A2 (en) 1992-08-20 1994-03-03 Schering Corporation Novel uses of il-4 and/or il-10, and antibodies against the same
US5922018A (en) 1992-12-21 1999-07-13 Artann Corporation Method for using a transrectal probe to mechanically image the prostate gland
US5373317B1 (en) 1993-05-28 2000-11-21 Welch Allyn Inc Control and display section for borescope or endoscope
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
DK0797676T3 (da) 1993-10-25 2006-04-18 Canji Inc Rekombinant adenoviral vektor og fremgangsmåder til anvendelse deraf
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
HU220344B (hu) 1994-07-05 2001-12-28 Steeno Research Group A/S Immunmodulátorok
WO1996018412A1 (en) 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
US5716804A (en) 1995-04-19 1998-02-10 Schering Corporation Mammalian interleukin-10 (IL-10) super-activating receptors; and variants
US6083919A (en) 1996-12-05 2000-07-04 University Of Florida Materials and methods for treating autoimmune disease
US6201880B1 (en) 1996-12-31 2001-03-13 Electro-Optical Sciences Method and apparatus for electronically imaging a tooth through transillumination by light
US5783567A (en) 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO1999047157A1 (en) 1998-03-17 1999-09-23 Schering Corporation Use of il-10 to treat major depressive disorder
US6528312B1 (en) 1998-05-06 2003-03-04 Transgene S.A. Use of G-actin for improving transfection of a polynucleotide into a cell
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US6165754A (en) 1999-06-08 2000-12-26 Cornell Research Foundation, Inc. Method of expressing an exogenous nucleic acid
US20050129669A1 (en) 1999-06-21 2005-06-16 Transkaryotic Therapies, Inc., A Massachusetts Corporation DNA construct for effecting homologous recombination and uses thereof
EP1278551A2 (en) 2000-04-21 2003-01-29 Vical Incorporated Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
AU2002217929A1 (en) 2000-11-28 2002-06-11 Sangamo Biosciences, Inc. Modulation of gene expression using insulator binding proteins
AU2002233239B2 (en) * 2000-12-13 2006-05-11 Merckle Gmbh Microparticles with an improved release profile and method for the production thereof
WO2002083080A2 (en) * 2001-04-17 2002-10-24 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
WO2002087594A1 (en) 2001-04-30 2002-11-07 The Regents Of The University Of California Non-viral vesicle vector for cardiac specific gene delivery
JP4578735B2 (ja) 2001-08-28 2010-11-10 オリンパス株式会社 内視鏡画像ファイリングシステム
JP2003146909A (ja) 2001-11-07 2003-05-21 Children's Hospital Of Philadelphia 治療用ポリペプチドに対する免疫寛容の誘導
CA2361462A1 (en) 2001-11-07 2003-05-08 Katherine A. High Induction of tolerance to a therapeutic polypeptide
US6967018B2 (en) 2002-01-11 2005-11-22 Applied Genetic Technologies Corporation Adiponectin gene therapy
US20070003518A1 (en) 2002-04-19 2007-01-04 Atkinson Mark A Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
GB0212648D0 (en) 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
US20040186357A1 (en) 2002-08-20 2004-09-23 Welch Allyn, Inc. Diagnostic instrument workstation
EP2801614B1 (en) 2002-08-29 2019-05-15 The Board of Trustees of the Leland Stanford Junior University Circular nucleic acid vectors and methods for making and using the same
US20040142893A1 (en) 2002-10-21 2004-07-22 Uichi Ikeda Methods for treating and preventing vascular disease
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US7530946B2 (en) 2003-08-15 2009-05-12 Scimed Life Systems, Inc. Compact endoscope
US7276486B2 (en) 2004-03-15 2007-10-02 Kimberly-Clark Worldwide, Inc. Compositions for vaginal treatment
BRPI0512814A (pt) 2004-07-01 2008-04-08 Univ Pittsburgh Of The Commmmo exosomas imunossupressivas
US20060073119A1 (en) 2004-09-01 2006-04-06 Avigen, Inc. Methods for treating neurodegenerative disorders
WO2006119170A2 (en) 2005-05-02 2006-11-09 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
EP1891103B1 (en) 2005-05-31 2009-12-23 The Regents of the University of Colorado Mutant il-10
ES2696824T3 (es) 2005-05-31 2019-01-18 Univ Colorado Regents Métodos para suministrar genes
WO2007016501A2 (en) 2005-08-01 2007-02-08 The University Of Chicago Compositions and method for brain specific targeted delivery of therapeutic agents
US20100196492A1 (en) 2007-03-08 2010-08-05 Green Jordan J Electrostatic coating of particles for drug delivery
US7846428B2 (en) 2007-10-05 2010-12-07 Merial Limited Articular cartilage gene therapy with recombinant vector encoding BMP-7
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
CN103260613B (zh) * 2010-12-15 2015-01-14 欧拉泰克工业有限责任公司 用于治疗炎症和疼痛的3-甲磺酰基丙腈
WO2013103966A1 (en) 2012-01-06 2013-07-11 The Regents Of The University Of Colorado, A Body Corporate Methods for the treatment of multiple sclerosis and other demyelinating disorders
SI3021873T1 (sl) 2013-07-18 2018-12-31 Xalud Therapeutics, Inc. Sestavek za zdravljenje vnetne sklepne bolezni
IL262195B2 (en) 2016-04-22 2023-09-01 Xalud Therapeutics Inc Methods and preparations for improving the anti-inflammatory effects of interleukin 10

Also Published As

Publication number Publication date
EP3369435B1 (en) 2019-09-04
PT3021873T (pt) 2018-12-10
US20160235816A1 (en) 2016-08-18
US20220313785A1 (en) 2022-10-06
DK3021873T3 (da) 2018-12-17
WO2015009955A1 (en) 2015-01-22
HUE046944T2 (hu) 2020-03-30
US20200093892A1 (en) 2020-03-26
PT3369435T (pt) 2019-12-05
SI3021873T1 (sl) 2018-12-31
EP3369435A1 (en) 2018-09-05
ES2760902T3 (es) 2020-05-18
US10512672B2 (en) 2019-12-24
JP7066669B2 (ja) 2022-05-13
EP3021873B1 (en) 2018-09-05
LT3021873T (lt) 2018-11-26
CY1122673T1 (el) 2021-03-12
CY1120946T1 (el) 2019-12-11
PL3021873T3 (pl) 2019-01-31
EP3021873A4 (en) 2016-11-30
JP2022031682A (ja) 2022-02-22
HRP20192043T1 (hr) 2020-02-07
HRP20181913T1 (hr) 2019-01-11
PL3369435T3 (pl) 2020-04-30
EP3021873B8 (en) 2018-10-24
RS57974B1 (sr) 2019-01-31
RS59735B1 (sr) 2020-02-28
JP2020037562A (ja) 2020-03-12
JP2016525522A (ja) 2016-08-25
EP3021873A1 (en) 2016-05-25
HUE042463T2 (hu) 2019-07-29
SI3369435T1 (sl) 2020-03-31
LT3369435T (lt) 2020-01-10
US20230158114A1 (en) 2023-05-25
ES2700826T3 (es) 2019-02-19

Similar Documents

Publication Publication Date Title
DK3030323T3 (da) Kdm1a-inhibitorer til behandlingen af sygdom
DK2968208T3 (da) Behandling af kataplexi
DK2984166T3 (da) Sammensætninger til behandling af mpsi
DK3043816T3 (da) Anti-b7-h1-antistoffer til behandling af tumorer
DK3076967T3 (da) Fremgangsmåder til behandling af residuelle symptomer på skizofreni
DK3269716T3 (da) Hidtil ukendte forbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske lidelser
DK2954051T3 (da) Modificeret kapsid til genoverførsel til behandling af nethinden
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
DK3027618T3 (da) Polymorf af syk-hæmmere
DK2961766T3 (da) Kvantificering af vaccinesammensætninger
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK2964315T3 (da) System til behandling af neuromotorisk dysfunktion
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK2961388T3 (da) Kombinationer af lægemidler
DK2968673T3 (da) Fremgangsmåde til decellularisering af vævstransplantater
DK3626270T3 (da) Behandling af kardiovaskulære sygdomme
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK2968221T3 (da) Farmaceutisk sammensætning af s-ketaminhydrochlorid
DK3021838T3 (da) Behandling af fedme
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3106150T3 (da) Forbedrede farmaceutiske sammensætninger af pimobendan
DK3027750T3 (da) Biokatalytisk sammensætning
DK3021839T3 (da) Sammensætninger for behandling af fibrose
DK3003366T3 (da) På hinanden følgende overlappende peptider til behandling af allergi overfor husstøvmider
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom